STOCK TITAN

[Form 4] Iridex Corp Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Iridex Corp Chief Financial Officer Romeo R. Dizon reported purchases of common stock on 08/26/2025. The filing shows two open-market buys: 750 shares at $1.26 and 250 shares at $1.25, for a total of 1,000 shares acquired. Following these transactions his beneficial ownership increased to 49,745 shares. The Form 4 was signed by an attorney-in-fact on 08/27/2025 and contains no derivative transactions or additional explanatory notes.

Iridex Corp Chief Financial Officer Romeo R. Dizon ha riportato acquisti di azioni ordinarie il 26/08/2025. La comunicazione indica due acquisti sul mercato: 750 azioni a $1,26 e 250 azioni a $1,25, per un totale di 1.000 azioni acquisite. In seguito a queste operazioni il suo possesso beneficiario è salito a 49.745 azioni. Il Modulo 4 è stato firmato da un procuratore il 27/08/2025 e non contiene transazioni su derivati né note esplicative aggiuntive.

Iridex Corp Director Financiero Romeo R. Dizon informó compras de acciones ordinarias el 26/08/2025. La presentación muestra dos compras en el mercado abierto: 750 acciones a $1,26 y 250 acciones a $1,25, por un total de 1.000 acciones adquiridas. Tras estas transacciones su propiedad beneficiaria aumentó a 49.745 acciones. El Formulario 4 fue firmado por un apoderado el 27/08/2025 y no contiene transacciones con derivados ni notas explicativas adicionales.

Iridex Corp의 최고재무책임자 Romeo R. Dizon이 2025-08-26에 보통주를 매수했다고 보고했습니다. 제출 서류에는 공개시장 매수 두 건이 기재되어 있습니다: 750주, 주당 $1.26250주, 주당 $1.25, 총 1,000주를 취득했습니다. 이 거래들로 그의 실질 소유는 49,745주로 증가했습니다. Form 4는 2025-08-27에 대리인이 서명했으며 파생상품 거래나 추가 설명은 포함되어 있지 않습니다.

Iridex Corp directeur financier Romeo R. Dizon a déclaré des achats d'actions ordinaires le 26/08/2025. Le dépôt indique deux achats sur le marché ouvert : 750 actions à 1,26 $ et 250 actions à 1,25 $, pour un total de 1 000 actions acquises. À la suite de ces opérations, sa propriété bénéficiaire est passée à 49 745 actions. Le formulaire 4 a été signé par un mandaté le 27/08/2025 et ne contient ni transactions sur dérivés ni notes explicatives supplémentaires.

Iridex Corp-Finanzvorstand Romeo R. Dizon meldete am 26.08.2025 Käufe von Stammaktien. Die Meldung weist zwei Käufe am offenen Markt aus: 750 Aktien zu $1,26 und 250 Aktien zu $1,25, insgesamt 1.000 Aktien. Nach diesen Transaktionen stieg sein wirtschaftliches Eigentum auf 49.745 Aktien. Das Formular 4 wurde am 27.08.2025 von einem Bevollmächtigten unterzeichnet und enthält keine Derivatgeschäfte oder zusätzliche erläuternde Hinweise.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: CFO Romeo Dizon purchased 1,000 IRIX shares in two transactions, modestly increasing his stake to 49,745 shares.

These are straightforward, small open-market purchases reported on a Form 4. The transactions total 1,000 shares at prices of $1.26 and $1.25, respectively, and there are no reported derivative positions or dispositions. For investors, this filing is a routine insider purchase disclosure rather than a material corporate event. It provides transparency on insider activity but does not, by itself, change the companys financial condition or capital structure.

TL;DR: Insider buying by a named executive; procedural filing signed by attorney-in-fact.

The Form 4 is properly completed: it identifies the reporting person, relationship to the issuer (CFO and director), the transaction dates, purchase codes, share amounts, and post-transaction holdings. The signature is by attorney-in-fact, dated 08/27/2025. No amendments or additional disclosures are present. From a governance perspective, the filing meets disclosure obligations and signals routine insider accumulation without accompanying commentary or plans.

Iridex Corp Chief Financial Officer Romeo R. Dizon ha riportato acquisti di azioni ordinarie il 26/08/2025. La comunicazione indica due acquisti sul mercato: 750 azioni a $1,26 e 250 azioni a $1,25, per un totale di 1.000 azioni acquisite. In seguito a queste operazioni il suo possesso beneficiario è salito a 49.745 azioni. Il Modulo 4 è stato firmato da un procuratore il 27/08/2025 e non contiene transazioni su derivati né note esplicative aggiuntive.

Iridex Corp Director Financiero Romeo R. Dizon informó compras de acciones ordinarias el 26/08/2025. La presentación muestra dos compras en el mercado abierto: 750 acciones a $1,26 y 250 acciones a $1,25, por un total de 1.000 acciones adquiridas. Tras estas transacciones su propiedad beneficiaria aumentó a 49.745 acciones. El Formulario 4 fue firmado por un apoderado el 27/08/2025 y no contiene transacciones con derivados ni notas explicativas adicionales.

Iridex Corp의 최고재무책임자 Romeo R. Dizon이 2025-08-26에 보통주를 매수했다고 보고했습니다. 제출 서류에는 공개시장 매수 두 건이 기재되어 있습니다: 750주, 주당 $1.26250주, 주당 $1.25, 총 1,000주를 취득했습니다. 이 거래들로 그의 실질 소유는 49,745주로 증가했습니다. Form 4는 2025-08-27에 대리인이 서명했으며 파생상품 거래나 추가 설명은 포함되어 있지 않습니다.

Iridex Corp directeur financier Romeo R. Dizon a déclaré des achats d'actions ordinaires le 26/08/2025. Le dépôt indique deux achats sur le marché ouvert : 750 actions à 1,26 $ et 250 actions à 1,25 $, pour un total de 1 000 actions acquises. À la suite de ces opérations, sa propriété bénéficiaire est passée à 49 745 actions. Le formulaire 4 a été signé par un mandaté le 27/08/2025 et ne contient ni transactions sur dérivés ni notes explicatives supplémentaires.

Iridex Corp-Finanzvorstand Romeo R. Dizon meldete am 26.08.2025 Käufe von Stammaktien. Die Meldung weist zwei Käufe am offenen Markt aus: 750 Aktien zu $1,26 und 250 Aktien zu $1,25, insgesamt 1.000 Aktien. Nach diesen Transaktionen stieg sein wirtschaftliches Eigentum auf 49.745 Aktien. Das Formular 4 wurde am 27.08.2025 von einem Bevollmächtigten unterzeichnet und enthält keine Derivatgeschäfte oder zusätzliche erläuternde Hinweise.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dizon Romeo R

(Last) (First) (Middle)
1212 TERRA BELLA AVENUE

(Street)
MOUNTAIN VIEW CA 94043

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IRIDEX CORP [ IRIX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/26/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/26/2025 P 750 A $1.26 49,495 D
Common Stock 08/26/2025 P 250 A $1.25 49,745 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Nilo De Castro, Attorney-in-fact for Romeo R. Dizon 08/27/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Iridex

NASDAQ:IRIX

IRIX Rankings

IRIX Latest News

IRIX Latest SEC Filings

IRIX Stock Data

22.09M
12.24M
27.64%
15.83%
1.68%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
MOUNTAIN VIEW